Between each numbered line are smaller lines representing individual units
The FDA also approves this medicine to reduce the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with Type 2 diabetes and cardiovascular disease or multiple risk factors for heart disease
Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,833 followers
A larger 360-capsule bottle costs $74.95, or $67.46 with a subscription
To view a copy of this licence, visit About this article Cite this article Zhang, J., Liu, M., Ou, H